NEXGEL, Inc. (NXGL) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-03-31
How it makes money
It generates revenue through contract manufacturing of bulk hydrogels and selling finished consumer products like Medagel, utilizing only 15% to 20% of its capacity.
It produces high water content polymers for medical diagnostics and drug delivery using electron beam cross-linking. Revenue comes from two primary sources: shipping bulk roll stock to medical brands for their own assembly, and selling finished consumer goods direct-to-consumer.
Profitability is highly sensitive to utilization of its 13,500 square foot facility. Currently operating at 15% to 20% capacity, it can produce up to 1.4 billion square inches of hydrogel annually without adding new infrastructure.
What protects it: the moat
It operates one of only two facilities capable of producing specialized electron beam hydrogels without the chemical cross-linking agents used by its rivals.
The company claims a technical moat by being one of only two manufacturers globally that utilize electron beam technology to cross-link hydrogels for medical and cosmetic use. This process avoids chemical cross-linking agents, which management asserts makes its patches significantly gentler on the skin than standard products.
This specialty allows it to meet rigid specifications for active ingredient release and moisture vapor transmission across more than 200 different chemical combinations.
What growth costs
It pursues a consumer brand roll-up strategy and medical device development, while research and development spending fell from $78 thousand to $2 thousand.
Growth is driven by acquiring existing consumer brands, such as the May 2024 purchase of beauty brand Silly George. It also maintains high inventory levels of components from sole-source suppliers to prevent production interruptions.
While current research spending is minimal at $2 thousand for the 2025 fiscal year, it expects costs to rise as it prepares the NEXDrape and NEXDerm medical devices for potential licensing partnerships rather than direct commercialization.
What could damage it
It relies heavily on Amazon and Shopify for distribution without long-term contracts, making its consumer revenue vulnerable to sudden platform termination.
The company lacks multi-year purchase agreements and operates entirely on a purchase order basis, allowing customers to stop orders at any time without penalty. This risk is amplified by its heavy dependence on the Amazon and Shopify marketplaces; if these platforms terminate their relationship or change terms, its primary consumer distribution channel would vanish.
About NEXGEL, Inc.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.